Notably, mavrilimumab demonstrated greater efficacy in early RA, consistent with CIA model findings where early anti-GM-CSF intervention prevented disease onset, whereas late intervention only mitigated disease severity 95. The gene discussed is CSF2; the disease is rheumatoid arthritis.